AU2009905147A0 - Pharmaceutical Compositions - Google Patents

Pharmaceutical Compositions

Info

Publication number
AU2009905147A0
AU2009905147A0 AU2009905147A AU2009905147A AU2009905147A0 AU 2009905147 A0 AU2009905147 A0 AU 2009905147A0 AU 2009905147 A AU2009905147 A AU 2009905147A AU 2009905147 A AU2009905147 A AU 2009905147A AU 2009905147 A0 AU2009905147 A0 AU 2009905147A0
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009905147A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Propanc Pty Ltd
Original Assignee
Propanc Pty Ltd
Filing date
Publication date
Application filed by Propanc Pty Ltd filed Critical Propanc Pty Ltd
Publication of AU2009905147A0 publication Critical patent/AU2009905147A0/en
Priority to EP10824316A priority Critical patent/EP2490711A4/en
Priority to CN201710885368.4A priority patent/CN107625957B/en
Priority to KR1020127012943A priority patent/KR101936439B1/en
Priority to DK16174383.6T priority patent/DK3095458T3/en
Priority to CN201080054056.5A priority patent/CN102639145B/en
Priority to EP16174383.6A priority patent/EP3095458B1/en
Priority to PT16174383T priority patent/PT3095458T/en
Priority to JP2012534496A priority patent/JP5871805B2/en
Priority to BR112012009521-8A priority patent/BR112012009521B1/en
Priority to RU2012120785/15A priority patent/RU2012120785A/en
Priority to NZ599996A priority patent/NZ599996A/en
Priority to ES16174383.6T priority patent/ES2692377T3/en
Priority to CA2814958A priority patent/CA2814958C/en
Priority to SG10201406651PA priority patent/SG10201406651PA/en
Priority to PE2012000530A priority patent/PE20121709A1/en
Priority to MYPI2012001764A priority patent/MY166634A/en
Priority to TR2018/15315T priority patent/TR201815315T4/en
Priority to PCT/AU2010/001403 priority patent/WO2011047434A1/en
Priority to AU2010310887A priority patent/AU2010310887B9/en
Priority to US13/502,917 priority patent/US9636359B2/en
Priority to MX2012004610A priority patent/MX355971B/en
Priority to IL219216A priority patent/IL219216A/en
Priority to CL2012001019A priority patent/CL2012001019A1/en
Priority to ZA2012/03689A priority patent/ZA201203689B/en
Priority to US15/462,655 priority patent/US10350239B2/en
Priority to HK18108670.0A priority patent/HK1249017A1/en
Priority to US16/428,581 priority patent/US20190388463A1/en
Priority to US17/862,120 priority patent/US20230137573A1/en
Abandoned legal-status Critical Current

Links

AU2009905147A 2009-10-22 2009-10-22 Pharmaceutical Compositions Abandoned AU2009905147A0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
MX2012004610A MX355971B (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent.
CA2814958A CA2814958C (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
MYPI2012001764A MY166634A (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
PE2012000530A PE20121709A1 (en) 2009-10-22 2010-10-22 A PHARMACEUTICAL COMPOSITION TO TREAT CANCER INCLUDING TRYPSINOGEN AND / OR CHEMOTRIPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VAINILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCING AGENT
DK16174383.6T DK3095458T3 (en) 2009-10-22 2010-10-22 PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING TRYPSINOGEN AND CHYMOTRYPSINOGEN
CN201710885368.4A CN107625957B (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
EP16174383.6A EP3095458B1 (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
PT16174383T PT3095458T (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
JP2012534496A JP5871805B2 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen.
BR112012009521-8A BR112012009521B1 (en) 2009-10-22 2010-10-22 PHARMACEUTICAL COMPOSITION AND USE OF CHYMOTRIPSINOGEN AND TRIPSINOGEN
RU2012120785/15A RU2012120785A (en) 2009-10-22 2010-10-22 PHARMACEUTICAL COMPOSITIONS
NZ599996A NZ599996A (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
TR2018/15315T TR201815315T4 (en) 2009-10-22 2010-10-22 Pharmaceutical composition comprising trypsinogen and chymotrypsinogen for the treatment of cancer.
EP10824316A EP2490711A4 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
SG10201406651PA SG10201406651PA (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
KR1020127012943A KR101936439B1 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
CN201080054056.5A CN102639145B (en) 2009-10-22 2010-10-22 Comprising trypsinogen and/or chymotrypsinogen and selected from selenium compound, class vanillic aldehyde compound and cytoplasm glycolysis reduce the pharmaceutical composition for being used to treat cancer of the activating agent of agent
ES16174383.6T ES2692377T3 (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
PCT/AU2010/001403 WO2011047434A1 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
AU2010310887A AU2010310887B9 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
US13/502,917 US9636359B2 (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
IL219216A IL219216A (en) 2009-10-22 2012-04-16 Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
CL2012001019A CL2012001019A1 (en) 2009-10-22 2012-04-20 Pharmaceutical composition comprising a protease proenzyme selected from at least trypsinogen and chymotrypsinogen and an active agent selected from at least one selenium compound, a vanilloid compound, a cytoplasmic glycolysis reducing agent and optionally a glycosidohydrolase; and use to treat cancer.
ZA2012/03689A ZA201203689B (en) 2009-10-22 2012-05-21 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a sytoplasmic glycolysis reduction agent
US15/462,655 US10350239B2 (en) 2009-10-22 2017-03-17 Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
HK18108670.0A HK1249017A1 (en) 2009-10-22 2018-07-04 A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
US16/428,581 US20190388463A1 (en) 2009-10-22 2019-05-31 Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent
US17/862,120 US20230137573A1 (en) 2009-10-22 2022-07-11 Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent

Publications (1)

Publication Number Publication Date
AU2009905147A0 true AU2009905147A0 (en) 2009-11-12

Family

ID=

Similar Documents

Publication Publication Date Title
HK1231408A1 (en) Pharmaceutical composition
HK1218881A1 (en) Pharmaceutical compositions
EP2416758B8 (en) Antimycotic pharmaceutical composition
EP2451274A4 (en) Pharmaceutical compositions
EP2240022A4 (en) Pharmaceutical compositions
GB0814695D0 (en) Pharmaceutical compositions
EP2373681A4 (en) Pharmaceutical compositions
PT2323623T (en) Pharmaceutical compositions
EP2379077A4 (en) Pharmaceutical composition
IL219018A0 (en) Pharmaceutical compositions
IL206487A0 (en) Pharmaceutical compositions
GB0919650D0 (en) Pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
AU2009905147A0 (en) Pharmaceutical Compositions
AU2013204097B2 (en) Pharmaceutical composition
AU2013204095B2 (en) Pharmaceutical composition
AU2010904996A0 (en) Pharmaceutical compositions
GB0901241D0 (en) Pharmaceutical compositions
GB0806283D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
EP2308842A4 (en) Pharmaceutical compositions
GB0902428D0 (en) Pharmaceutical methods & compositions